Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 26Breast Neoplasms 26Lung Neoplasms 24Colonic Neoplasms 18Head and Neck Neoplasms 16Rectal Neoplasms 14Prostatic Neoplasms 11Sarcoma 10Neoplasm Metastasis 9Pancreatic Neoplasms 8Neoplasms 7Mouth Neoplasms 7Melanoma 7Esophageal Neoplasms 7Adenomatous Polyposis Coli 7Ovarian Neoplasms 6Glioblastoma 6Precancerous Conditions 5Neuroblastoma 5Liver Neoplasms 5Central Nervous System Neoplasms 5Carcinoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Oropharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Celecoxib × Clear all
NCT00099047 2016-12-30

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 7 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡